CSL (OTCMKTS:CSLLY) Sees Strong Trading Volume - Should You Buy?

Key Points

• CSL Limited experienced a trading volume surge, with approximately 383,803 shares traded, marking a 300% increase from the previous session's volume.
• Analyst ratings for CSL saw a downgrade from Zacks Research, which lowered the stock from a "hold" rating to a "strong sell", while the average rating remains at "Moderate Buy."
• The company's financial stability includes a quick ratio of 1.12, a current ratio of 2.46, and a debt-to-equity ratio of 0.50.

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) saw unusually-high trading volume on Monday . Approximately 383,803 shares traded hands during trading, an increase of 300% from the previous session's volume of 96,066 shares.The stock last traded at $65.51 and had previously closed at $65.38.

Wall Street Analyst Weigh In

Separately, Zacks Research cut CSL from a "hold" rating to a "strong sell" rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy".

CSL Price Performance

The stock has a fifty day moving average of $77.51 and a 200-day moving average of $78.19. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.